Back to Search Start Over

LBA12 Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Initial results from a registrational phase II study.

Authors :
Zhou, Q.
Meng, X.
Sun, L.
Huang, D.
Yang, N.
Yu, Y.
Zhao, M.
Zhuang, W.
Hu, Y.
Pan, Y.
Sun, M.
Shan, J.
Guo, R-H.
Chu, Q.
Xu, C.
Lin, J.
Huang, J.
Huang, M.
Shen, Y.
Wu, Y-L.
Source :
Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1662-S1662. 1p.
Publication Year :
2023

Subjects

Subjects :
*NON-small-cell lung carcinoma

Details

Language :
English
ISSN :
09237534
Volume :
34
Database :
Academic Search Index
Journal :
Annals of Oncology
Publication Type :
Academic Journal
Accession number :
173758464
Full Text :
https://doi.org/10.1016/j.annonc.2023.10.584
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details